Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Abstract Background The PI 3-kinase (PI3K) pathway has been implicated as a target for melanoma therapy. Methods Given the high degree of genetic heterogeneity in melanoma, we sought to understand the breadth of variation in PI3K signalling in the large NZM panel of early passage cell lines develope...

Full description

Bibliographic Details
Main Authors: Khanh B. Tran, Sharada Kolekar, Anower Jabed, Patrick Jaynes, Jen-Hsing Shih, Qian Wang, Jack U. Flanagan, Gordon W. Rewcastle, Bruce C. Baguley, Peter R. Shepherd
Format: Article
Language:English
Published: BMC 2021-02-01
Series:BMC Cancer
Subjects:
mTOR
PI 3-kinase
PI3Kα
PI3Kδ
PIK3CA
PIK3CD
Online Access:https://doi.org/10.1186/s12885-021-07826-4

Internet

https://doi.org/10.1186/s12885-021-07826-4

Similar Items